GEA
ITCI

Glen Eagle Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Glen Eagle Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$1.24K – 659
2017
Q2 		$1.24K Hold
100
– – ﹤0.01% 555
2017
Q1 		$1.63K Buy
+100
New +$1.45K ﹤0.01% 517

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Glen Eagle Advisors's ITCI Position: Q3 2017 in Review

Glen Eagle Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2017, closing a stake of 100 shares — an estimated $1.24K sold.

Glen Eagle Advisors first reported a position in ITCI in Q1 2017 and held it in 2 quarters. The position peaked at $1.63K in Q1 2017. 137 funds tracked by Wall St. Rank hold ITCI as of Q3 2017.

  • Glen Eagle Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2017 after selling out during the quarter.
  • Glen Eagle Advisors sold 100 Intra-Cellular Therapies Inc. shares in Q3 2017, an estimated $1.24K.
  • Glen Eagle Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2017 and held it in 2 quarters.
  • Glen Eagle Advisors's Intra-Cellular Therapies Inc. position peaked at $1.63K in Q1 2017.
  • 137 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2017.

Based on Glen Eagle Advisors's 13F filing for Q3 2017, filed 13 Aug 2024.